Poniard halves workforce and struggles on with picoplatin
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals is to reduce its workforce by more than a half to 21 employees and is focusing all remaining resources to advance the ongoing clinical development of its anticancer picoplatin.